In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

The tool, which allows conventional searching of data-independent acquisition mass spec data, previously worked only with AB Sciex TripleTOF instruments.

The clinical trial is designed to validate that biomarkers, measured in routine urine tests, effectively predict genetic mutations in drug-metabolizing enzymes.

South African researchers uncover bone cancer in an ancient hominin ancestor.

The current arrangement builds on an existing agreement signed last year that allowed Garvan to use DNAnexus' platform for its genomics activities.

The company continues to build evidence for the added sensitivity offered by its urine- and blood-based liquid biopsy approach in an effort to engage clinicians.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

Researchers identified two cases with biallelic mutations in MSH3 in exome sequences from more than 100 patients with unexplained colorectal adenomatous polyposis.

The NIH is seeking new regional medical centers to help enroll and manage a portion of the up to 1 million volunteers expected to participate in the initiative.

Editas Medicine has appointed Akshay Vaishnaw to its board of directors. 

He is Executive VP of R&D and CMO at Alnylam Pharmaceuticals. Vaishnaw received his MD from the University of Wales and a PhD in molecular immunology from the University of London. 

Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.

ACMG said in a position statement that NIPS can replace conventional screening for Patau, Edwards, and Down syndrome in most women.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

The company uses multiple-reaction monitoring mass spectrometry to measure exosome-bound proteins that can predict a woman's risk of preterm delivery.

The firm saw decreases in its core diagnostics business that were offset in part by revenues from newly-acquired Magellan Diagnostics.

The company has raised venture funding to support commercialization of a variety of blood-based cancer assays in Taiwan, but has yet to publish data validating its approach.

The companies will jointly offer services and equipment solutions for the development, high-volume manufacture, and launch of multiplexed in vitro diagnostics.

The deal sets up a multi-year collaboration on hematopoietic stem cell and T-cell editing with the San Raffaele Telethon Institute for Gene Therapy.

Researchers working on the Human Functional Genomics Project have begun to unravel genetic relationships and variations in human immune response. 

The firm's reagents and disposables business was the biggest gainer, with a 12 percent revenue increase in the quarter. 

The molecular diagnostics company said it will use the proceeds to continue commercializing its Cologuard colorectal cancer test, and to develop new products.